According to Sino Biopharmaceutical's latest financial reports the company has A$3.18 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | A$2.93 B | -18.69% |
2022-12-31 | A$3.60 B | 5.46% |
2021-12-31 | A$3.41 B | 4.35% |
2020-12-31 | A$3.27 B | -16.12% |
2019-12-31 | A$3.90 B | 118.11% |
2018-12-31 | A$1.79 B | -8.16% |
2017-12-31 | A$1.95 B | 13.83% |
2016-12-31 | A$1.71 B | 72.61% |
2015-12-31 | A$0.99 B | 25.85% |
2014-12-31 | A$0.78 B | 74.62% |
2013-12-31 | A$0.45 B | 36.27% |
2012-12-31 | A$0.33 B | 37.19% |
2011-12-31 | A$0.24 B | -32.71% |
2010-12-31 | A$0.35 B | 33.01% |
2009-12-31 | A$0.26 B | -21.41% |
2008-12-31 | A$0.34 B | 31.66% |
2007-12-31 | A$0.26 B | -4.95% |
2006-12-31 | A$0.27 B | -8.23% |
2005-12-31 | A$0.29 B | 421.24% |
2004-12-31 | A$57.37 M | 14.47% |
2003-12-31 | A$50.12 M | -21.49% |
2002-12-31 | A$63.84 M | 47.77% |
2001-12-31 | A$43.2 M | 50.82% |
2000-12-31 | A$28.64 M | 136.67% |
1999-12-31 | A$12.1 M |